PT-141, also known as bremelanotide, is a synthetic peptide that treats sexual dysfunction by activating pathways in the brain rather than increasing blood flow like traditional medications. It’s sold under the brand name Vyleesi and was approved by the FDA on June 21, 2019, as a prescription treatment for low sexual desire in premenopausal women. The drug works differently from anything else on the market, which is why it generates so much curiosity.
How PT-141 Works in the Brain
Most sexual dysfunction drugs work on blood vessels. Medications like sildenafil (Viagra) relax blood vessels in the genitals to improve blood flow, a purely physical effect. PT-141 takes a completely different approach. It’s a melanocortin receptor agonist, meaning it activates specific receptors in the central nervous system called MC3R and MC4R. These receptors sit primarily in the brain, particularly in the hypothalamus, a region that regulates hormones, arousal, and motivated behavior.
When PT-141 binds to these receptors, it activates neurons in the hypothalamus. In research terms, it increases something called c-Fos immunoreactivity, which is a marker scientists use to confirm that brain cells have been turned on. The practical result is that the drug influences sexual desire and arousal at the level of the brain itself, not just the plumbing. This central nervous system mechanism makes PT-141 the first drug in its class to target the motivational and desire component of sexual function rather than the mechanical one.
What PT-141 Is Approved For
The FDA-approved version of PT-141, branded as Vyleesi, is indicated for hypoactive sexual desire disorder (HSDD) in premenopausal women. This condition involves persistently low sexual desire that causes personal distress and isn’t explained by another medical condition, a relationship problem, or a medication side effect. Vyleesi is manufactured by Cosette Pharmaceuticals and is available by prescription only.
It’s worth noting that the approval is narrow. Vyleesi is not approved for postmenopausal women, and it is not approved for men. Early clinical research did explore PT-141 for male erectile dysfunction, with results suggesting it could help initiate erections through its central nervous system mechanism. However, development for men did not progress to FDA approval. Some men still obtain PT-141 through compounding pharmacies or off-label channels, but this use falls outside the drug’s approved indication.
Dosage and How It’s Used
Vyleesi is not a daily pill. It’s a subcutaneous injection, meaning you inject it just under the skin of the abdomen or thigh using a prefilled autoinjector. The recommended dose is 1.75 mg, taken as needed at least 45 minutes before anticipated sexual activity. You should not take more than one dose in a 24-hour period, and no more than 8 doses per month are recommended.
This on-demand dosing schedule sets it apart from flibanserin (Addyi), the other FDA-approved drug for low sexual desire in women, which requires a daily pill taken at bedtime. For people who prefer not to commit to daily medication, the as-needed approach can be appealing. The tradeoff is the injection itself, which some people find inconvenient or uncomfortable.
Side Effects
Nausea is the most common side effect by a wide margin. In clinical trials, about 40% of patients experienced nausea, and it was most pronounced after the first injection. For many users, the nausea decreases with subsequent doses, but it’s significant enough that it was one of the primary complaints during trials. Flushing affected about 20% of patients, injection site reactions occurred in roughly 13%, and headache was reported in about 11%.
PT-141 can also cause a temporary increase in blood pressure. This is a known pharmacological effect of melanocortin receptor activation. For most people the increase is modest and resolves on its own, but it’s a concern for anyone with uncontrolled high blood pressure or cardiovascular risk factors. The drug may also cause hyperpigmentation, or darkening of the skin on the gums and face, particularly with repeated use. This effect is related to PT-141’s origin as a derivative of alpha-MSH, a hormone involved in skin pigmentation.
How It Differs From Viagra and Similar Drugs
The distinction is fundamental. PDE5 inhibitors like sildenafil are peripheral vasodilators. They relax smooth muscle in blood vessels, increasing blood flow to the genitals. They don’t change desire, motivation, or arousal at the psychological level. If the underlying issue is purely mechanical (difficulty achieving or maintaining an erection due to blood flow), these drugs work well.
PT-141 initiates sexual response through a central nervous system mechanism. It acts on the brain’s arousal circuitry rather than on blood vessels. This makes it potentially useful for people whose primary issue is desire rather than physical response. Early research even explored combining PT-141 with PDE5 inhibitors in men with erectile dysfunction, since the two drugs target entirely different parts of the sexual response pathway. The theory is that addressing both brain-level desire and genital blood flow could help people who don’t respond to either approach alone.
PT-141 Outside the Prescription Market
A significant amount of interest in PT-141 comes from people encountering it through peptide clinics, compounding pharmacies, or online vendors rather than through a standard Vyleesi prescription. Compounding pharmacies sometimes sell bremelanotide in vial form for subcutaneous injection, often marketed to both men and women for sexual enhancement. These products are not FDA-approved versions of the drug, and their purity, dosing accuracy, and safety profiles can vary.
If you’re considering PT-141 from any source, the key things to understand are the blood pressure effects, the high rate of nausea (especially initially), and the monthly dosing limit of 8 times. The drug is genuinely novel in how it works, but “works through the brain” doesn’t mean it’s without physical side effects. The cardiovascular considerations in particular deserve a conversation with a provider who knows your health history.